Status:

ACTIVE_NOT_RECRUITING

Antibiotic Prophylaxis in Patients Undergoing Elective Total Knee Arthroplasty- Multi-center Trial

Lead Sponsor:

Duke University

Collaborating Sponsors:

American Association of Hip and Knee Surgeons

Orthopedic Research and Education Foundation

Conditions:

Arthropathy of Knee

Antibiotic Prophylaxis

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

The Antibiotic Prophylaxis in Patients Undergoing Elective Total Knee Arthroplasty (TKA): Multi-Center Trial is a study that will compare the effectiveness of various perioperative strategies for anti...

Detailed Description

Total joint arthroplasty (TJA), is one of the most successful operations in modern medicine; however, it remains an expensive procedure in an era of constrained health care resources. Arthritis affect...

Eligibility Criteria

Inclusion

  • Patient is ≥ 18 years of age
  • Patient has no open wounds on operative leg
  • Patient is scheduled to undergo elective total knee arthroplasty for posttraumatic, osteoarthritis, avascular necrosis, and/or inflammatory arthritis
  • Patient does not have active infection on the operative leg, the operative joint
  • Patient is willing to cooperate and follow study protocol and visit schedule

Exclusion

  • Patient is ≤ 18 years of age
  • Patient is pregnant
  • Patient is unable to provide written consent
  • Patient has psychiatric disorder that precludes safe study participation or that necessitates confinement in a custodial environment at home or in a chronic care facility
  • Patient has traumatic injury that requires emergent or urgent total knee arthroplasty (e.g. fracture)
  • Patient has active infections in the operative leg/joint
  • Patient has severe dementia
  • Suspicion of illicit drug abuse by patient. Patients who use prescription cannabinoids are not excluded from enrollment.
  • ASA score of 5 \& 6
  • No application of topical antibiotic powder such as vancomycin or antibiotic beads in surgical wound
  • Intra-operative re-dosing other than specified re-dosing intervals or without excessive blood loss (\<1500mL)
  • History of prior native septic knee arthritis

Key Trial Info

Start Date :

October 24 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2025

Estimated Enrollment :

1770 Patients enrolled

Trial Details

Trial ID

NCT03283878

Start Date

October 24 2017

End Date

December 1 2025

Last Update

November 24 2025

Active Locations (14)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (14 locations)

1

University of California, San Francisco

San Francisco, California, United States, 94143

2

Emory University

Atlanta, Georgia, United States, 30322

3

University of Maryland St. Joseph Medical Center & Orthopedic Associates

Towson, Maryland, United States, 21204

4

University Of Mississippi Medical Center

Jackson, Mississippi, United States, 39216